v3.26.1
Interim consolidated statement of comprehensive income - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Continuing operations    
Revenue from contracts with customers $ 477,350 $ 390,359
Cost of sales (217,001) (181,736)
Gross profit 260,349 208,623
Other income 40,000 0
Research and development costs (123,828) (81,583)
Selling and marketing expenses (58,358) (48,973)
Manufacturing and distribution costs (28,713) (18,849)
General and administration costs (48,663) (47,723)
Other gains/(losses)(net) 5,575 (1,105)
Operating profit 46,362 10,390
Finance income 2,274 3,616
Finance costs (19,388) (18,842)
Profit/(loss) before income tax 29,248 (4,836)
Income tax benefit 9,082 2,544
Profit/(loss) for the period 38,330 (2,292)
Profit/(loss) for the period attributable to:    
Owners of Telix Pharmaceuticals Limited 38,330 (2,292)
Items that will not be reclassified to profit or loss in subsequent periods:    
Changes in the fair value of investments at fair value through other comprehensive income 1,207 (1,381)
Items to be reclassified to profit or loss in subsequent periods:    
Exchange differences on translation of foreign operations (30,079) 6,928
Total comprehensive income for the period 9,458 3,255
Total comprehensive income for the period attributable to:    
Owners of Telix Pharmaceuticals Limited $ 9,458 $ 3,255
Earnings per share [abstract]    
Basic earnings/(loss) per share from continuing operations after income tax attributable to the ordinary equity holders of the Company (in dollars per share) $ 0.1130 $ (0.0068)
Diluted earnings/(loss) per share from continuing operations after income tax attributable to the ordinary equity holders of the Company (in dollars per share) $ 0.1074 $ (0.0068)